Crucell (CRCL.AS) shareholders on Tuesday supported changes in the Dutch biotech's statutes and supervisory board, which will help Johnson & Johnson take control of the company if its 1.75 billion euro offer succeeds. The resolutions were an important pre-condition for the deal as they will give Johnson & Johnson effective control of Crucell immediately when the deal closes and also afford it taxation benefits. A majority of Crucell shareholders voted to amend the company's articles of association and nominate mostly employees from U.S. healthcare group Johnson & Johnson as supervisory board members if J&J declares its offer unconditional.
Source
